

Case Report

Statin Cessation Improves Cognition, Function and Epilepsy in An Elderly Woman

Hannah Mathew*

Internal Medicine, North Middlesex University Hospital, UK

*Corresponding author: Hannah Mathew

Internal Medicine, North Middlesex University Hospital, UK.

Email: h2mathew@gmail.com

Received: September 05, 2024

Accepted: September 26, 2024

Published: October 03, 2024

Introduction

Statins are one of the most commonly prescribed cholesterol-lowering agents in the world. In the UK, around 7.5 million adults are prescribed a statin, both for primary and secondary prevention [1]. However, researchers have questioned the efficacy of cholesterol-lowering as a strategy for cardiovascular disease [2,3], and there is evidence that high levels of total cholesterol is associated with lower all-cause mortality in terms of cancers, infection and death [4-6] This is especially true in elderly patients, where there is an inverse correlation between cholesterol levels and mortality. [7,8] Cholesterol is an essential substance that is needed by the brain and nerves for myelin production, as well as cell-to-cell communication with the help of lipid rafts. It is unsurprising that cholesterol lowering comes with a variety of neuropsychiatric side effects that have been documented in the literature. Some of these side effects include dementia-like symptoms, seizures, depression, suicidal ideation, homicidal ideation, insomnia, and aggression. [9-11] There is even evidence that stopping a statin has reversed dementia-like symptoms in elderly patients, symptoms of which returned with rechallenge [12,13].

Case Report

An 82-year-old woman with a history of Hypertension, Type 2 Diabetes, Ischaemic Heart Disease, Heart Failure, Multiple Myocardial Infarctions, Epilepsy, Anxiety, Depression and Dementia presented to hospital with general functional decline, and increased seizure episodes. Her family reported that she

became non-verbal for the past 1 month, and was not recognizing family members as much. She was diagnosed with Dementia 9 years ago, and CT scan revealed age related involutional changes, and chronic microvascular ischaemic changes.

Liver functions were abnormal (ALT 338, AST 116, ALP 67), therefore the statin was suspended. Post suspension of statin, patients' cognition improved significantly, so did her liver functions, seizures frequency.

Parameter	Before	After
Seizures	3-4 Generalized Tonic Clonic Seizures a month	No seizures reported
Liver functions	ALT 338, AST 116, ALP 67	ALT 55, AST 20, ALP 56
Cognition	Non-verbal, not responsive, or talking or recognizing family members	Started talking again, recognizing and responding to family members, asking to go home
Functional status	Reduced mobility, bed-bound	Started moving and sitting out on a chair

Discussion

There is increasing evidence that statins have severe neuropsychiatric and cognitive side effects. An analysis of trials done on statins for primary prevention reveals that statins only have a benefit of 0.35% reduction in cardiovascular events [14]. Even in patients with established cardiovascular disease, it only provides an average mortality benefit of 3-4 days [15] It is important to note that a documented side effect of statins is type 2

diabetes mellitus, which is the most potent risk factor for cardiovascular events [16,17]. Given this evidence, it is important for clinicians to carefully analyze the risks of prescribing a statin, especially in elderly patients or those with neurocognitive background. I suggest that statins are inappropriate in elderly patients, and should be stopped, as they can cause muscle toxicity as well as neurocognitive side effects - which is a major risk factor for cognitive and functional decline in elderly patients. In this case, this patient with multiple co-morbidities and extreme frailty presented with a symptom of advanced dementia (non-verbal, unresponsive, not talking to family members), and stopping the statin significantly improved her cognition and functional status.

References

1. Kulkarni S, Watts MM, Kostapanos M. Statins. *BMJ*. 2024; 384: e072584.
2. Ravnskov U, de Lorgeril M, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, et al. LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature. *Expert Review of Clinical Pharmacology*. 2018; 11: 959–970.
3. Ravnskov U, de Lorgeril M, DuBroff R. Cholesterol paradox: a correlate does not a surrogate make. *Evid Based Med*. 2017; 22: 15-19.
4. Yi SW, Yi JJ, Ohrr H. Total cholesterol and all-cause mortality by sex and age: a prospective cohort study among 12.8 million adults. *Sci Rep*. 2019; 9: 1596.
5. Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, Harcombe Z, Kendrick M, et al. The LDL paradox: Higher LDLCholesterol is Associated with Greater Longevity. *A Epidemiol Public Health*. 2020; 3: 1040.
6. Ravnskov U, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, Hynes N, Kendrick M, Langsjoen PH, Malhotra A, Mascitelli L, McCully KS, Ogushi Y, Okuyama H, Rosch PJ, Schersten T, Sultan S, Sundberg R. Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review. *BMJ Open*. 2016; 6: e010401.
7. Ravnskov U, de Lorgeril M, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, et al. LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature. *Expert Rev Clin Pharmacol*. 2018; 11: 959-970.
8. Xuxiao Y, Blais JE, Ng VW, Castle D, Hayes JF, Wei Y, et al. Association between statins and the risk of suicide attempt, depression, anxiety, and seizure: A population-based, self-controlled case series study. *J Affect Disord*. 2023; 320: 421-7.
9. Cham S, Koslik HJ, Golomb BA. Mood, Personality, and Behavior Changes During Treatment with Statins: A Case Series. *Drug Saf Case Rep*. 2016; 3: 1.
10. Padala KP, Padala PR, McNeilly DP, Geske JA, Sullivan DH, Potter JF. The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer's dementia: a prospective withdrawal and rechallenge pilot study. *Am J Geriatr Pharmacother*. 2012; 10: 296-302.
11. Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. *Pharmacotherapy*. 2009; 29: 800-11.
12. Chou R, Cantor A, Dana T, Wagner J, Ahmed AY, Fu R, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA*. 2022; 328: 754-771.
13. Kristensen ML, Christensen PM, Hallas J. The effect of statins on average survival in randomised trials, an analysis of end point postponement. *BMJ Open*. 2015; 5: e007118.
14. Laakso M, Fernandes Silva L. Statins and risk of type 2 diabetes: mechanism and clinical implications. *Front Endocrinol (Lausanne)*. 2023; 14: 1239335.
15. Global Cardiovascular Risk Consortium; Magnussen C, Ojeda FM, Leong DP, Alegre-Diaz J, Amouyel P, et al. Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality. *N Engl J Med*. 2023; 389: 1273-1285.